Clinical efficacy results
| Total (n=112) | Group 1 (n=47) | Group 2 (n=65) | P value | |
| Mortality at 90 days | 10.7% | 18.6% | 5.0% | 0.048 |
| Mortality at 30 days | 9.4% | 15.6% | 4.9% | 0.093 |
| Clinical improvement at 6 days | 24.1% | 28.9% | 20.6% | 0.323 |
| Length of hospital stay (days)* | 14 (10–25) | 11 (9–18) | 15 (11–28) | 0.044 |
| % of patients with radiological improvement after 10 days* | 67.9% | 71.4% | 65.3% | 0.554 |
| Admission to the ICU after tocilizumab† | 14.6% | 15.0% | 14.3% | 0.922 |
| Length of stay in ICU (days) | 16 (11–28) | 18 (11–28) | 13 (11–23) | 0.600 |
6-day efficacy results are based on patients with follow-up at the indicated period.
*Excluding patients transferred to other centres or deaths.
†Excluding patients who were already in the ICU at the time of administration.